The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Clinical Predictors of Ketamine Response in Treatment-Resistant Major Depression
Open accessAbstract
OBJECTIVE: The N-methyl-D-aspartate receptor antagonist ketamine has rapid antidepressant effects in treatment-resistant major depressive disorder (MDD) and bipolar depression. Clinical predictors may identify those more likely to benefit from ketamine within clinically heterogeneous populations. METHOD: Data were analyzed from 4 studies of treatment-resistant inpatients with DSM-IV-TR-diagnosed MDD or bipolar I or II depression. Patients who were currently experiencing a moderate-to-severe major depressive episode were enrolled between November 2004 and March 2013. All subjects received a single subanesthetic (0.5 mg/kg) ketamine infusion over 40 minutes. Patients were analyzed at the 230-minute postinfusion time point (n = 108), at day 1 (n = 82), and at day 7 (n = 71). Univariate Pearson correlations were performed for each variable with percent change from baseline in the 17-item Hamilton Depression Rating Scale (HDRS). Multivariate linear regression was then conducted for statistically significant predictors (P ≤ .05, 2-tailed). RESULTS: Higher body mass index correlated with greater HDRS improvement at 230 minutes (standardized β = -0.30, P = .004) and at day 1 (standardized β = -0.37, P = .001), but not at day 7 (standardized β = -0.18, P = .10). Family history of an alcohol use disorder in a first-degree relative was associated with greater HDRS improvement at day 1 (standardized β = -0.27, P = .014) and day 7 (standardized β = -0.41, P < .001). No prior history of suicide attempt(s) was associated with greater improvement only at day 7 (standardized β = 0.28, P = .01). The overall statistical model explained 13%, 23%, and 36% of HDRS percent change variance at 230 minutes, day 1, and day 7, respectively. CONCLUSIONS: Despite its post hoc nature, this study identified several clinical correlates of ketamine's rapid and durable antidepressant effects. Further investigation of these relationships is critical for individualized treatment of depression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Elevated body mass index (BMI) has been found to be a predictor of response to ketamine,196 but in another study197 elevated BMI was not correlated with ketamine response, and presence of metabolic syndrome was negatively correlated with ketamine response.”
From Ketamine as an antidepressant: Overview of its mechanisms of action and potential predictive biomarkers (2020) · cites this paper as [196]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Self-citationKrystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881
Moghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793
Maeng, S., Zarate, C. A., Du, J., Schloesser, R. J., McCammon, J., Chen, G., & Manji, H. K. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.05.028 · Cited by 1,103
Self-citationLi, N., Liu, R.-J., Dwyer, J. M., Banasr, M., Lee, B., Son, H., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.12.015 · Cited by 1,082
Diazgranados, N., Ibrahim, L., Brutsche, N. E., Newberg, A., Kronstein, P., Khalife, S., Kammerer, W. A., Quezado, Z., Luckenbaugh, D. A., Salvadore, G., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.90 · Cited by 963
Self-citationZarate, C. A., Brutsche, N. E., Ibrahim, L., Franco-Chaves, J., Diazgranados, N., Cravchik, A., Selter, J., Marquardt, C. A., Liberty, V., & Luckenbaugh, D. A. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.12.010 · Cited by 811
Self-citationSignaling pathways underlying the rapid antidepressant actions of ketamine
Duman, R. S., Li, N., Liu, R.-J., Duric, V., & Aghajanian, G. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.08.044 · Cited by 537
Cited by
Sorted by citations
McIntyre, R. S., Rosenblat, J. D., Nemeroff, C. B., Sanacora, G., Murrough, J. W., Berk, M., Brietzke, E., Dodd, S., Gorwood, P., Ho, R., et al. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20081251 · Cited by 731
Self-citationA brief history of the development of antidepressant drugs: From monoamines to glutamate.
Hillhouse, T. M., & Porter, J. H. (2015) · Experimental and Clinical Psychopharmacology · doi:10.1037/a0038550 · Cited by 663
Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression.
Newport, D. J., Carpenter, L. L., McDonald, W. M., Potash, J. B., Tohen, M., Nemeroff, C. B., & The APA Council of Research Task Force on Novel Biomarkers and Treatments (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15040465 · Cited by 598
Sex differences in depression: Insights from clinical and preclinical studies
Eid, R. S., Gobinath, A. R., & Galea, L. A. M. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2019.01.006 · Cited by 486
Ballard, E. D., Ionescu, D. F., Vande Voort, J. L., Niciu, M. J., Richards, E. M., Luckenbaugh, D. A., Brutsché, N. E., Ameli, R., Furey, M. L., & Zarate, C. A. (2014) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2014.07.027 · Cited by 286
Self-citationSex differences and the neurobiology of affective disorders
Rubinow, D. R., & Schmidt, P. J. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-018-0148-z · Cited by 286
Matveychuk, D., Thomas, R. K., Swainson, J., Khullar, A., MacKay, M.-A., Baker, G. B., & Dursun, S. M. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320916657 · Cited by 209
Iadarola, N. D., Niciu, M. J., Richards, E. M., Vande Voort, J. L., Ballard, E. D., Lundin, N. B., Nugent, A. C., Machado-Vieira, R., & Zarate, C. A. (2015) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622315579059 · Cited by 201
Self-citationAntidepressant Medications and Weight Change: A Narrative Review
Gill, H., Gill, B., El‐Halabi, S., Chen-Li, D. C. J., Lipsitz, O., Rosenblat, J. D., Rheenen, T. E. V., Rodrigues, N. B., Mansur, R. B., Majeed, A., et al. (2020) · Obesity · doi:10.1002/oby.22969 · Cited by 209
Kiraly, D. D., Horn, S. R. G.-V., Dam, N. T. V., Costi, S., Kirshenbaum, J. S., Kim‐Schulze, S., Patel, M., Hodes, G. E., Russo, S. J., Mérad, M., et al. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.31 · Cited by 189
Ionescu, D. F., Bentley, K. H., Eikermann, M., Taylor, N., Akeju, O., Swee, M. B., Pavone, K. J., Petrie, S. R., Dording, C., Mischoulon, D., et al. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.09.037 · Cited by 179
Self-citationGlutamate and its receptors in the pathophysiology and treatment of major depressive disorder
Niciu, M. J., Ionescu, D. F., Richards, E. M., & Zarate, C. A. (2013) · Journal of Neural Transmission · doi:10.1007/s00702-013-1130-x · Cited by 163
Self-citationAntidepressant actions of ketamine: from molecular mechanisms to clinical practice
Monteggia, L. M., & Zarate, C. (2015) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2014.12.004 · Cited by 149
Self-citationMurrough, J. W., Burdick, K. E., Levitch, C. F., Perez, A. M., Brallier, J. W., Chang, L. C., Foulkes, A., Charney, D. S., Mathew, S. J., & Iosifescu, D. V. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2014.298 · Cited by 142
Shiroma, P. R., THURAS, P. D., Wels, J., Albott, C. S., Erbes, C. R., Tye, S. J., & Lim, K. O. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-00897-0 · Cited by 124
Rong, C., Park, C., Rosenblat, J. D., Subramaniapillai, M., Zuckerman, H., Fus, D., Lee, Y. L., Pan, Z., Brietzke, E., Mansur, R. B., et al. (2018) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph15040771 · Cited by 114
Administration of ketamine for unipolar and bipolar depression
Kraus, C., Rabl, U., Vanicek, T., Carlberg, L., Popovic, A., Spies, M., Bartova, L., Gryglewski, G., Papageorgiou, K., Lanzenberger, R. R., et al. (2017) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2016.1254802 · Cited by 114
The role of adipokines in the rapid antidepressant effects of ketamine
Machado-Vieira, R., Gold, P. W., Luckenbaugh, D. A., Ballard, E. D., Richards, E. M., Henter, I. D., De Sousa, R. T., Niciu, M. J., Yuan, P., & Zarate, C. A. (2017) · Molecular Psychiatry · doi:10.1038/mp.2016.36 · Cited by 102
Self-citationJelen, L. A., & Stone, J. M. (2021) · International Review of Psychiatry · doi:10.1080/09540261.2020.1854194 · Cited by 112
Therapeutic Modulation of Glutamate Receptors in Major Depressive Disorder
Jaso, B. A., Niciu, M. J., Iadarola, N. D., Lally, N., Richards, E. M., Park, M., Ballard, E. D., Nugent, A. C., Machado‐Vieira, R., & Zarate, C. A. (2016) · Current Neuropharmacology · doi:10.2174/1570159x14666160321123221 · Cited by 101
Self-citationLarge-Scale Transcriptomics Studies Provide Insight Into Sex Differences in Depression
Seney, M. L., Glausier, J. R., & Sibille, E. L. (2021) · Biological Psychiatry · doi:10.1016/j.biopsych.2020.12.025 · Cited by 100
Efficacy of ketamine therapy in the treatment of depression
Mandal, S., Sinha, V., & Goyal, N. (2019) · Indian Journal of Psychiatry · doi:10.4103/psychiatry.indianjpsychiatry_484_18 · Cited by 94
Rostami, R., Kazemi, R., Nitsche, M. A., Gholipour, F., & Salehinejad, M. A. (2017) · Clinical Neurophysiology · doi:10.1016/j.clinph.2017.07.395 · Cited by 93
Ketamine and other potential glutamate antidepressants
Dutta, A., McKie, S., & Deakin, J. F. W. (2014) · Psychiatry Research · doi:10.1016/j.psychres.2014.10.028 · Cited by 92
Moaddel, R., Luckenbaugh, D. A., Xie, Y., Villaseñor, A., Brutsche, N. E., Machado-Vieira, R., Ramamoorthy, A., Lorenzo, M. P., Garcia, A., Bernier, M., et al. (2015) · Psychopharmacology · doi:10.1007/s00213-014-3669-0 · Cited by 86
Self-citationPrice, R. B., Kissel, N., Baumeister, A., Rohac, R., Woody, M. L., Ballard, E. D., Zarate, C. A., Deakin, W., Abdallah, C. G., Feder, A., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01757-7 · Cited by 82
Self-citationAssessing measures of suicidal ideation in clinical trials with a rapid-acting antidepressant
Ballard, E. D., Luckenbaugh, D. A., Richards, E. M., Walls, T. L., Brutsché, N. E., Ameli, R., Niciu, M. J., Vande Voort, J. L., & Zarate, C. A. (2015) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2015.06.003 · Cited by 80
“The 230-min time point is often used in ketamine analyses because it assesses the short-term effects of ketamine infusion after psychotomimetic effects have dissipated (Niciu et al., 2014; Zarate et al., 2006).”
Self-citationPennybaker, S. J., Niciu, M. J., Luckenbaugh, D. A., & Zarate, C. A. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.10.026 · Cited by 76
Self-citationMedeiros, G. C., Gould, T. D., Prueitt, W. L., Nanavati, J., Grunebaum, M. F., Farber, N. B., Singh, B., Selvaraj, S., Machado-Vieira, R., Achtyes, E. D., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01652-1 · Cited by 75
Self-citationSumner, R. L., Chacko, E., McMillan, R. L., Spriggs, M. J., Anderson, C., Chen, J., French, A., Jung, S., Rajan, A., Malpas, G. A., et al. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881121998321 · Cited by 77
Investigating the Role of Glutamate in Obsessive-Compulsive Disorder: Current Perspectives
Karthik, S., Sharma, L. P., & Narayanaswamy, J. C. (2020) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s211703 · Cited by 78
Freeman, M. P., Papakostas, G. I., Hoeppner, B. B., Mazzone, E., Judge, H., Cusin, C., Mathew, S. J., Sanacora, G., Iosifescu, D. V., DeBattista, C., et al. (2019) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2019.01.010 · Cited by 73
Inflammation, stress and depression: An exploration of ketamine’s therapeutic profile
Johnston, J. N., Greenwald, M. S., Henter, I. D., Kraus, C., Mkrtchian, A., Clark, N. G., Park, L. T., Gold, P. W., Zarate, C. A., & Kadriu, B. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103518 · Cited by 68
Self-citationKetamine for depression: evidence, challenges and promise
Zarate, C. A., & Niciu, M. J. (2015) · World Psychiatry · doi:10.1002/wps.20269 · Cited by 63
Self-citationStrong, C. E., & Kabbaj, M. (2018) · Neurobiology of Stress · doi:10.1016/j.ynstr.2018.09.001 · Cited by 63
Hull, T. D., Malgaroli, M., Gazzaley, A., Akiki, T. J., Madan, A., Vando, L., Arden, K., Swain, J., Klotz, M., & Paleos, C. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.07.004 · Cited by 58
Niciu, M. J., Luckenbaugh, D. A., Ionescu, D. F., Richards, E. M., Voort, J. L. V., Ballard, E. D., Brutsché, N. E., Furey, M. L., & Zarate, C. A. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyu039 · Cited by 56
Self-citationCharacterizing the course of suicidal ideation response to ketamine
Ballard, E. D., Yarrington, J. S., Farmer, C., Richards, E. M., Machado‐Vieira, R., Kadriu, B., Niciu, M. J., Yuan, P., Park, L., & Zarate, C. A. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.07.077 · Cited by 57
Self-citationVidal, S. I., Gex‐Fabry, M., Bancila, V., Michalopoulos, G., Warrot, D., Jermann, F., Dayer, A. G., Virginie Sterpenich, A., Schwartz, S., Vutskits, L., et al. (2018) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000960 · Cited by 51
Strong, C. E., Schoepfer, K. J., Dossat, A. M., Saland, S. K., Wright, K. N., & Kabbaj, M. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.05.003 · Cited by 49
Antidepressant effects of curcumin-coated iron oxide nanoparticles in a rat model of depression
Khadrawy, Y. A., Hosny, E. N., Magdy, M., & Mohammed, H. S. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174384 · Cited by 51
Esterlis, I., Holmes, S. E., Sharma, P., Krystal, J. H., & DeLorenzo, C. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.08.025 · Cited by 50
Effects of Serial Ketamine Infusions on Corticolimbic Functional Connectivity in Major Depression
Vasavada, M. M., Loureiro, J. R., Kubicki, A., Sahib, A. K., Wade, B., Hellemann, G., Espinoza, R. T., Congdon, E. L., Narr, K. L., & Leaver, A. M. (2020) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2020.06.015 · Cited by 51
Ketamine and suicidal ideation in depression: Jumping the gun?
Rajkumar, R., Fam, J., Yeo, E. Y. M., & Dawe, G. S. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.05.003 · Cited by 43
Medeiros, G. C., Matheson, M., Demo, I., Reid, M. J., Matheson, S., Twose, C., Smith, G. S., Gould, T. D., Zarate, C. A., Barrett, F. S., et al. (2023) · The Lancet Psychiatry · doi:10.1016/s2215-0366(23)00183-9 · Cited by 49
Self-citationBody Mass Index as a Moderator of Treatment Response to Ketamine for Major Depressive Disorder
Freeman, M. P., Hock, R. S., Papakostas, G. I., Judge, H., Cusin, C., Mathew, S. J., Sanacora, G., Iosifescu, D. V., DeBattista, C., Trivedi, M. H., et al. (2020) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001209 · Cited by 44
Personalized use of ketamine and esketamine for treatment-resistant depression
Medeiros, G. C., Demo, I., Goes, F. S., Zarate, C. A., & Gould, T. D. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03180-8 · Cited by 43
Self-citationFortress, A. M., Smith, I. M., & Pang, K. C. H. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.05.009 · Cited by 38
Jesus‐Nunes, A. P., Leal, G. C.-G., Correia‐Melo, F. S., Vieira, F., Mello, R. P., Caliman‐Fontes, A. T., Echegaray, M. V. F., Marback, R. F., Guerreiro‐Costa, L. N. F., Souza‐Marques, B., et al. (2022) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2836 · Cited by 38
Lucchese, A. C., Sarin, L. M., Magalhães, E. T. P., Sant, L. C. D., Puertas, C. B., Tuena, M. A., Nakahira, C., Fava, V. A. R., Delfino, R. S., Surjan, J. C., et al. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881120978398 · Cited by 36
Neurobiological biomarkers of response to ketamine
Kadriu, B., Ballard, E. D., Henter, I. D., Murata, S., Gerlus, N., & Zarate, C. A. (2020) · Advances in pharmacology · doi:10.1016/bs.apha.2020.05.003 · Cited by 36
Self-citationIntranasal esketamine: From origins to future implications in treatment-resistant depression
Sanders, B. J., & Brula, A. Q. (2021) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2021.02.020 · Cited by 37
Sex-dependent metabolism of ketamine and ( 2R,6R )-hydroxynorketamine in mice and humans
Highland, J. N., Farmer, C., Zanos, P., Lovett, J., Zarate, C. A., Moaddel, R., & Gould, T. D. (2021) · Journal of Psychopharmacology · doi:10.1177/02698811211064922 · Cited by 36
Self-citationKetamine‐An Update on Its Clinical Uses and Abuses
Xu, J., & Lei, H. (2014) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12363 · Cited by 35
Chen, M., Kao, C., Tsai, S., Li, C., Lin, W.-C., Hong, C., Bai, Y., Tu, P., & Su, T. (2020) · Genomics · doi:10.1016/j.ygeno.2020.12.030 · Cited by 33
Ketamine in Bipolar Disorder: A Review
Wilkowska, A., Szałach, Ł. P., & Cubała, W. J. (2020) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s282208 · Cited by 35
Dale, R. M., Bryant, K. A., & Thompson, N. R. (2020) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001149 · Cited by 29
Nakamura, T., Tomita, M., Horikawa, N., Ishibashi, M., Uematsu, K., Hiraki, T., Abe, T., & Uchimura, N. (2021) · Neuropsychopharmacology Reports · doi:10.1002/npr2.12165 · Cited by 28
Ketamine for bipolar depression: an updated systematic review
Fancy, F., Haikazian, S., Johnson, D. E., Chen-Li, D. C. J., Levinta, A., Husain, M. I., Mansur, R. B., & Rosenblat, J. D. (2023) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253231202723 · Cited by 29
Chen, M., Chang, W.-C., Lin, W.-C., Tu, P., Li, C., Bai, Y., Tsai, S., Huang, W.-S., & Su, T. (2020) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa056 · Cited by 28
Fitzgerald, P. J., Kounelis-Wuillaume, S., Gheidi, A., Morrow, J. D., Spencer-Segal, J. L., & Watson, B. O. (2021) · Stress · doi:10.1080/10253890.2021.1871600 · Cited by 27
Xu, A. J., Niciu, M. J., Lundin, N. B., Luckenbaugh, D. A., Ionescu, D. F., Richards, E. M., Voort, J. L. V., Ballard, E. D., Brutsché, N. E., Machado‐Vieira, R., et al. (2015) · Neural Plasticity · doi:10.1155/2015/858251 · Cited by 27
Self-citationSerafini, G., Amore, M., & Rihmer, Z. (2015) · Neuroimmunology and Neuroinflammation · doi:10.4103/2347-8659.157955 · Cited by 27
Chen, M., Wu, H.-J., Li, C., Lin, W.-C., Bai, Y., Tsai, S., Hong, C., Tu, P., Cheng, C., & Su, T. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.11.045 · Cited by 24
Tarrés-Gatius, M., Miquel-Rio, L., Campa, L., Artigas, F., & Castañé, A. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-01110-y · Cited by 26
Sex differences in ketamine's therapeutic effects for mood disorders: A systematic review
Benitah, K. C., Siegel, A. N., Lipsitz, O., Rodrigues, N. B., Meshkat, S., Lee, Y. L., Mansur, R. B., Nasri, F., Lui, L. M. W., McIntyre, R. S., et al. (2022) · Psychiatry Research · doi:10.1016/j.psychres.2022.114579 · Cited by 24
Meyer, T., Brunovský, M., Horáček, J., Novák, T., Andrashko, V., Seifritz, E., & Olbrich, S. (2021) · Clinical Neurophysiology · doi:10.1016/j.clinph.2021.01.030 · Cited by 25
Zhou, Y., Liu, W., Zheng, W., Wang, C., Zhan, Y., Lan, X., Zhang, B., Zhang, C., & Ning, Y. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.01.001 · Cited by 23
Lipsitz, O., McIntyre, R. S., Rodrigues, N. B., Lee, Y. L., Gill, H., Subramaniapillai, M., Kratiuk, K., Nasri, F., Mansur, R. B., & Rosenblat, J. D. (2020) · CNS Spectrums · doi:10.1017/s1092852920002102 · Cited by 24
Ketamine for Treatment of Suicidal Ideation and Reduction of Risk for Suicidal Behavior
Mallick, F., & McCullumsmith, C. B. (2016) · Current Psychiatry Reports · doi:10.1007/s11920-016-0680-7 · Cited by 22
Effect of Ketamine on Rumination in Treatment-Resistant Depressive Patients
Vidal, S. I., Jermann, F., Aubry, J., Richard-Lepouriel, H., & Kosel, M. (2020) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001305 · Cited by 22
Ketamine and esketamine for crisis management in patients with depression: Why, whom, and how?
Lengvenytė, A., Strumila, R., Olié, É., & Courtet, P. (2022) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2022.02.004 · Cited by 21
Chan, L. F., Eu, C. L., Soh, S. Y., Maniam, T., Kadir, Z. S., Chong, B. T. W., Loo, J. L., Sharip, S., WONG, V. C. W., Loo, T. H., et al. (2018) · Journal of Psychiatric Practice · doi:10.1097/pra.0000000000000316 · Cited by 19
Dose‐dependent effects of esketamine on brain activity in awake mice: A BOLD phMRI study
Kawazoe, K., McGlynn, R. P., Felix, W., Sevilla, R. S., Liao, S., Kulkarni, P., & Ferris, C. F. (2022) · Pharmacology Research & Perspectives · doi:10.1002/prp2.1035 · Cited by 18
Exploring Predictors of Ketamine Response in Adolescent Treatment-Resistant Depression
Lineham, A., Avila-Quintero, V. J., Bloch, M. H., & Dwyer, J. B. (2024) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2023.0047 · Cited by 17
A review of ketamine’s role in ECT and non-ECT settings
Jankauskas, V., Necyk, C., Chue, J., & Chue, P. S. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s157233 · Cited by 19
Beaudequin, D. A., Can, A., Dutton, M., Jones, M., Gallay, C. C., Schwenn, P., Yang, C., Forsyth, G., Simcock, G. P., Hermens, D. F., et al. (2020) · BMC Psychiatry · doi:10.1186/s12888-020-02925-1 · Cited by 17
Pennybaker, S. J., Roach, B. J., Fryer, S. L., Badathala, A., Wallace, A., Mathalon, D. H., & Marton, T. F. (2021) · Psychopharmacology · doi:10.1007/s00213-021-05939-z · Cited by 17
Lundin, N. B., Niciu, M. J., Luckenbaugh, D. A., Ionescu, D., Richards, E. M., Voort, J. V., Brutsché, N. E., Machado‐Vieira, R., & Zarate, C. A. (2014) · Pharmacopsychiatry · doi:10.1055/s-0034-1377042 · Cited by 18
Self-citationPan, Y., Gorenflo, M. P., Davis, P. B., Kaelber, D. C., Luca, S. M. D., & Xu, R. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03033-4 · Cited by 23
New use for an old drug: oral ketamine for treatment-resistant depression
Swiatek, K., Jordan, K. M., & Coffman, J. H. (2016) · BMJ Case Reports · doi:10.1136/bcr-2016-216088 · Cited by 16
“Novel Psychopharmacology for Depressive Disorders”
Fornaro, M., Berardis, D. D., Anastasia, A., & Fusco, A. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-981-33-6044-0_22 · Cited by 15
Neurocognitive Changes after Sustained Ketamine Administration in Children with Chronic Pain
Bredlau, A. L. (2015) · Journal of Palliative Care & Medicine · doi:10.4172/2165-7386.1000215 · Cited by 15
Molecular Mechanism and Clinical Relevance of Ketamine as Rapid‐Acting Antidepressant
Pešić, V., Petrović, J., & Jukić, M. M. (2016) · Drug Development Research · doi:10.1002/ddr.21335 · Cited by 15
Ohtani, Y., Tani, H., Nomoto‐Takahashi, K., Yatomi, T., Yonezawa, K., Tomiyama, S., Nagai, N., Kusudo, K., Honda, S., Moriyama, S., et al. (2024) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13734 · Cited by 14
Key considerations in the pharmacological management of treatment-resistant depression
Yavi, M., Henter, I. D., Park, L. T., & Zarate, C. A. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1951225 · Cited by 14
Self-citationUnderwood, M. D., Bakalian, M. J., Johnson, V. L., Kassir, S. A., Ellis, S. P., Mann, J. J., & Arango, V. (2020) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa009 · Cited by 13
Asch, R. H., Abdallah, C. G., Carson, R. E., & Esterlis, I. (2025) · Neuropsychopharmacology · doi:10.1038/s41386-024-01913-3 · Cited by 13
Future Directions for Pharmacotherapies for Treatment-resistant Bipolar Disorder
Dodd, S., Fernandes, B. S., & Dean, O. M. (2015) · Current Neuropharmacology · doi:10.2174/1570159x13666150630175841 · Cited by 14
Roméo, B., Choucha, W., Fossati, P., & Rotgé, J. (2016) · L Encéphale · doi:10.1016/j.encep.2016.06.005 · Cited by 13
Miller, E. A., Afshar, H. T., Mishra, J., McIntyre, R. S., & Ramanathan, D. (2024) · Psychiatry Research · doi:10.1016/j.psychres.2024.115858 · Cited by 12
Comstock, S. M., Vaidya, J. G., & Niciu, M. J. (2019) · Chronic Stress · doi:10.1177/2470547019865267 · Cited by 12
Self-citationLeptin, obesity, and response to ketamine
Rashidian, H., Rosenblat, J. D., McIntyre, R. S., & Mansur, R. B. (2019) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2019.109773 · Cited by 11
Brunelin, J., Iceta, S., Plaze, M., Raphaël Gaillard, B., Simon, L., Suaud‐Chagny, M., Galvão, F., & Poulet, E. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.562137 · Cited by 11
Chen, M., Cheng, C., Li, C., Tsai, S., Lin, W., Bai, Y., & Su, T. (2022) · Psychiatry Research · doi:10.1016/j.psychres.2022.114749 · Cited by 11
Echegaray, M. V. F., Mello, R. P., Magnavita, G. M., Leal, G. C.-G., Correia‐Melo, F. S., Jesus‐Nunes, A. P., Vieira, F., Bandeira, I. D., Caliman‐Fontes, A. T., Telles, M., et al. (2023) · Trends in Psychiatry and Psychotherapy · doi:10.47626/2237-6089-2022-0593 · Cited by 11
Zheng, W., Zhou, Y., Wang, C., Lan, X., Zhang, B., Zhou, S., Yan, S., Yang, M., Nie, S., & Ning, Y. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320973794 · Cited by 11
Alcohol Use Disorder as a Possible Predictor of Electroconvulsive Therapy Response
Aksay, S. S., Hambsch, M., Janke, C., Bumb, J. M., Kranaster, L., & Sartorius, A. (2016) · Journal of Ect · doi:10.1097/yct.0000000000000366 · Cited by 11
Salloum, N. C., Gott, B. M., & Conway, C. R. (2017) · Brain stimulation · doi:10.1016/j.brs.2017.06.001 · Cited by 10
Yonezawa, K., Uchida, H., Yatomi, T., Ohtani, Y., Nomoto‐Takahashi, K., Nakajima, S., Mimura, M., & Tani, H. (2023) · Pharmacopsychiatry · doi:10.1055/a-2179-8884 · Cited by 9
Metadata
- Authors
- Niciu, M. J., Luckenbaugh, D. A., Ionescu, D. F., Guevara, S., Machado-Vieira, R., Richards, E. M., Brutsche, N. E., Nolan, N. M., & Zarate, C. A.
- Affiliations
- National Institutes of Health (US)
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2014-05-15
- Volume
- 75
- Issue
- 05
- Pages
- e417-e423
- ISSN
- 0160-6689 (ISSN-L)
- PMC
- PMC4310499
- OpenAlex
- W2005055479
- Cited by
- 165
- References
- 41
- Citations by year
- 2026: 10 · 2025: 15 · 2024: 13 · 2023: 12 · 2022: 12 · 2021: 21 · 2020: 21 · 2019: 7 · 2018: 12 · 2017: 8 · 2016: 10 · 2015: 16 · 2014: 7
- FWCI
- 9.96
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Alliance for Research on Schizophrenia and Depression
- National Institutes of Health (Z99 MH999999)
- National Institute of Mental Health
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- ketamine, treatment-resistant depression, major depressive disorder, bipolar depression, antidepressant response, predictors of treatment response, body mass index, family history of alcoholism, suicide attempt history, NMDA receptor antagonists, rapid antidepressant effects, personalized treatment
- MeSH terms
- Adult, Bipolar Disorder, Major Depressive Disorder, Depressive Disorder, Major, Female, Follow-Up Studies, Humans, Infusions, Intravenous, Ketamine, Male, Middle Aged, Psychiatric Status Rating Scales, Severity of Illness Index, Time Factors, Body Mass Index, Receptors, N-Methyl-D-Aspartate, Treatment Outcome, Excitatory Amino Acid Antagonists, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
